Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.
Type:
Grant
Filed:
July 9, 2009
Date of Patent:
November 29, 2011
Assignee:
Pfizer Inc
Inventors:
Tanisha D. Blake, Bruce C. Hamper, Wei Huang, James R. Kiefer, Jr., Joseph B. Moon, Bradley E. Neal, Kirk L. Olson, Matthew J. Pelc, Barbara A. Schweitzer, Atli Thorarensen, John I. Trujillo, Steven R. Turner
Abstract: The invention provides a process for producing a compound of formula (I), wherein Y is selected from the group consisting of CH3, CH2OH, CH2CH2OH, CH2Br and Br; comprising the steps of: (i) reacting a compound of formula (II), wherein OX represents hydroxy or O?M+, in which M+ is a cation selected from Li+, Na+ and K+, and Y is as defined above; with trans-cinnamaldehyde (III), in the presence of a secondary amine compound; then (ii) treating the product of the preceding step with acid to afford the compound of formula (I). The above process may also be used in the production of tolterodine and fesoterodine, which are useful in the treatment of overactive bladder.
Type:
Grant
Filed:
May 21, 2007
Date of Patent:
November 29, 2011
Assignee:
Pfizer Inc.
Inventors:
Jens Bertil Ahman, Barry Richard Dillon, Alan John Pettman
Abstract: The invention relates to 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazole compounds of the Formula I: or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.
Type:
Grant
Filed:
November 11, 2009
Date of Patent:
November 22, 2011
Assignee:
Wyeth LLC
Inventors:
Simon Nicolas Haydar, Patrick Michael Andrae, Heedong Yun, Albert Jean Robichaud
Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
Type:
Grant
Filed:
August 25, 2008
Date of Patent:
November 22, 2011
Assignee:
Pfizer Inc.
Inventors:
Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
Abstract: Materials and methods for preparing (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid and structurally related compounds via enzymatic kinetic resolution are disclosed.
Type:
Grant
Filed:
November 22, 2010
Date of Patent:
October 25, 2011
Assignee:
Pfizer Inc.
Inventors:
Shanghui Hu, Carlos Alberto Martinez, Junhua Tao, William Eugene Tully, Patrick Kelleher, Yves Dumond
Abstract: The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.
Type:
Grant
Filed:
October 18, 2007
Date of Patent:
October 25, 2011
Assignee:
Pfizer Inc.
Inventors:
Lorraine Kathleen Fay, Douglas S. Johnson, Suzanne Ross Kesten, Scott E. Lazerwith, Mark Anthony Morris, Cory Michael Stiff, Marvin Jay Meyers, Lijuan Jane Wang
Abstract: The present invention provides a compound of formula 1: wherein R1 is CF3, R2 is H? R3 is H.
Type:
Grant
Filed:
November 11, 2010
Date of Patent:
October 11, 2011
Assignee:
Pfizer Inc.
Inventors:
Ronald S. Michalak, Mahmut Levent, Frederick J. Vyverberg, Ara R. Boyajian, Panolil Raveendranath, Michel Cantin, Alan Stockton, Michael W. Winkley, Mousumi Ghosh, Christoph Dehnhardt, Charles Guinosso
Abstract: A complex of an echinocandin compound with a carbohydrate is described having improved thermal stability and water solubility. A process for making the echinocandin/carbohydrate complex is also described as well as the use of the complex in pharmaceutical formulations and treatments of fungal infections.
Type:
Grant
Filed:
May 21, 2009
Date of Patent:
September 20, 2011
Assignee:
Eli Lilly and Company
Inventors:
Larry Arnold Larew, Nathaniel Milton, James Lawrence Sabatowski, Kenneth Philip Moder
Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
Type:
Grant
Filed:
July 1, 2010
Date of Patent:
September 6, 2011
Assignee:
Pfizer Inc
Inventors:
Alan Daniel Brown, Mark Edward Bunnage, Paul Alan Glossop, Kim James, Charlotte Alice Louise Lane, Russel Andrew Lewthwaite, Ian Brian Moses, David Anthony Price, Nicholas Murray Thomson
Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Type:
Grant
Filed:
November 2, 2006
Date of Patent:
August 30, 2011
Assignee:
Rinat Neuroscience Corporation
Inventors:
Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Leigh Jones Collier, Arnon Rosenthal
Abstract: The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF.
Type:
Grant
Filed:
March 16, 2009
Date of Patent:
August 30, 2011
Assignee:
Pfizer Inc.
Inventors:
David L. Shelton, Patrick William Mantyh
Abstract: The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R1, R2, R3, and R4 are as described herein.
Type:
Grant
Filed:
September 9, 2009
Date of Patent:
July 12, 2011
Assignee:
Pfizer Inc
Inventors:
John William Benbow, Jihong Lou, Jeffrey Allen Pfefferkorn, Meihua Mike Tu
Abstract: This invention provides a compound of the formula (I): wherein Het represents a heterocyclic group having one nitrogen atom, to which B binds directly, and from 4 to 7 carbon atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of substituents ?1; A represents an alkylene group having from 1 to 4 carbon atoms; B represents a covalent bond or an alkylene group having from 1 to 5 carbon atoms; R1 represents an isopropyl group, a n-propyl group or a cyclopentyl group; R2 represents a methyl group, a fluorine atom or a chlorine atom; R3 independently represents (i) an oxo group, a hydroxy group, an amino group, an alkylamino group or a carboxyl group; (ii) a cycloalkyl group having from 3 to 8 carbon atoms, and said cycloalkyl group being substituted by 1 to 5 substituents, or (iii) a heterocyclic group having from 3 to 8 atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 5 substituents, and n is 1,
Abstract: The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.
Type:
Grant
Filed:
May 9, 2008
Date of Patent:
June 21, 2011
Assignee:
Pfizer Inc.
Inventors:
Patrick Robert Verhoest, Caroline Proulx-Lafrance
Abstract: This invention provides a compound of the formula These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.
Type:
Grant
Filed:
November 9, 2007
Date of Patent:
June 21, 2011
Assignee:
Pfizer Inc.
Inventors:
Koji Ando, Andrew Anthony Calabrese, Matthew Alexander James Duncton, Kentaro Futatsugi, Misato Hirano, Satochi Nagayama
Abstract: A process for forming drug multiparticulates having improved drug crystallinity is disclosed, comprising modifying a conventional melt-congeal process by adding a volatile cospecies either to the molten mixture or to the process atmosphere, or to both.
Type:
Grant
Filed:
December 3, 2004
Date of Patent:
May 31, 2011
Assignee:
Pfizer Inc.
Inventors:
Dwayne T. Friesen, Marshall D. Crew, Roderick J. Ray, Leah E. Appel
Abstract: A compound of Formula (I): or a pharmaceutically and/or veterinarily acceptable derivative thereof, wherein R1, R2, R3, R4, R5, and R8 are as defined above.
Type:
Grant
Filed:
December 15, 2006
Date of Patent:
May 17, 2011
Assignee:
Pfizer Limited
Inventors:
Andrew Simon Bell, Charlotte Alice Louise Lane, Charles Eric Mowbray
Abstract: A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.
Type:
Grant
Filed:
October 12, 2005
Date of Patent:
May 10, 2011
Assignee:
Pfizer, Inc.
Inventors:
Antone John deBettencourt, III, Evgenyi Yur'evich Shalaev
Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor: wherein the variables are described in the specification.
Type:
Grant
Filed:
October 5, 2007
Date of Patent:
May 3, 2011
Assignee:
Wyeth LLC
Inventors:
William Ronald Solvibile, Ji-In Kim, Marla Jean Williams, Jonathan Laird Gross, Albert Jean Robichaud